CYTK vs. AUR
CYTK (Cytokinetics, Incorporated) and AUR (Aurora Innovation, Inc.) are both stocks. CYTK operates in Biotechnology (Healthcare), while AUR operates in Information Technology Services (Technology). Over the past 5 years, CYTK returned 28.77%/yr vs -7.09%/yr for AUR. At a 0.28 correlation, their price movements are largely independent.
Performance
CYTK vs. AUR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CYTK achieves a 13.77% return, which is significantly lower than AUR's 78.12% return.
CYTK
- 1D
- 2.23%
- 1M
- -6.23%
- YTD
- 13.77%
- 6M
- 8.64%
- 1Y
- 123.05%
- 3Y*
- 23.91%
- 5Y*
- 28.77%
- 10Y*
- 24.12%
AUR
- 1D
- -1.58%
- 1M
- 4.75%
- YTD
- 78.12%
- 6M
- 49.67%
- 1Y
- 17.73%
- 3Y*
- 65.83%
- 5Y*
- -7.09%
- 10Y*
- —
CYTK vs. AUR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CYTK Cytokinetics, Incorporated | 13.77% | 35.08% | -43.66% | 82.21% | 0.53% | 94.95% |
AUR Aurora Innovation, Inc. | 78.12% | -39.05% | 44.16% | 261.16% | -89.25% | 12.60% |
Correlation
The correlation between CYTK and AUR is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.31 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.29 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since May 11, 2021 | 0.28 |
Fundamentals
CYTK:
$8.91B
AUR:
$13.32B
CYTK:
-$6.84
AUR:
-$0.44
CYTK:
82.86
AUR:
3.23K
CYTK:
$105.82M
AUR:
$4.00M
CYTK:
$95.60M
AUR:
$163.00M
CYTK:
-$748.97M
AUR:
-$882.00M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CYTK vs. AUR — Risk / Return Rank
CYTK
AUR
CYTK vs. AUR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cytokinetics, Incorporated (CYTK) and Aurora Innovation, Inc. (AUR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CYTK | AUR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.74 | ||
| Sortino ratioReturn per unit of downside risk | +2.54 | ||
| Omega ratioGain probability vs. loss probability | 1.40 | 1.10 | +0.30 |
| Calmar ratioReturn relative to maximum drawdown | 8.25 | 0.42 | +7.83 |
| Martin ratioReturn relative to average drawdown | 18.81 | 0.71 | +18.10 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CYTK | AUR | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.03 | 0.29 | +1.74 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.41 | -0.08 | +0.49 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.36 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.02 | -0.08 | +0.06 |
Drawdowns
CYTK vs. AUR - Drawdown Comparison
The maximum CYTK drawdown since its inception was -97.09%, roughly equal to the maximum AUR drawdown of -93.34%. Use the drawdown chart below to compare losses from any high point for CYTK and AUR.
Loading charts...
Drawdown Indicators
| CYTK | AUR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.09% | -93.34% | -3.75% |
Max Drawdown (1Y)Largest decline over 1 year | -15.01% | -42.53% | +27.52% |
Max Drawdown (3Y)Largest decline over 3 years | -72.39% | -63.00% | -9.39% |
Max Drawdown (5Y)Largest decline over 5 years | -72.39% | -93.34% | +20.95% |
Max Drawdown (10Y)Largest decline over 10 years | -72.39% | — | — |
Current DrawdownCurrent decline from peak | -33.10% | -60.02% | +26.92% |
Average DrawdownAverage peak-to-trough decline | -76.05% | -67.46% | -8.59% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.57% | 24.96% | -18.39% |
Volatility
CYTK vs. AUR - Volatility Comparison
The current volatility for Cytokinetics, Incorporated (CYTK) is 10.73%, while Aurora Innovation, Inc. (AUR) has a volatility of 25.68%. This indicates that CYTK experiences smaller price fluctuations and is considered to be less risky than AUR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CYTK | AUR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.73% | 25.68% | -14.95% |
Volatility (6M)Calculated over the trailing 6-month period | 33.05% | 49.78% | -16.73% |
Volatility (1Y)Calculated over the trailing 1-year period | 60.93% | 61.75% | -0.82% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 70.24% | 90.59% | -20.35% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 67.99% | 89.95% | -21.96% |
Dividends
CYTK vs. AUR - Dividend Comparison
Neither CYTK nor AUR has paid dividends to shareholders.
Financials
CYTK vs. AUR - Financials Comparison
This section allows you to compare key financial metrics between Cytokinetics, Incorporated and Aurora Innovation, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CYTK and AUR have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AUR has higher volatility (25.68%) compared to CYTK (10.73%). In terms of maximum drawdown, CYTK dropped -97.09% vs AUR's -93.34%.
CYTK currently has the higher Sharpe Ratio (2.03 vs 0.29), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CYTK and AUR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer